	US 12,421,296 B2
	Activin receptor type IIB variants and uses thereof
Maureen O'Connor-McCourt, Montreal (CA); Vannakambadi K. Ganesh, Montreal (CA); Gilles Tremblay, Montreal (CA); and Gauthier Schang, Montreal (CA)
Assigned to 35PHARMA Inc., Montreal (CA)
Filed by 35PHARMA Inc., Montreal (CA)
Filed on Feb. 29, 2024, as Appl. No. 18/591,918.
Application 18/591,918 is a division of application No. 18/160,787, filed on Jan. 27, 2023, granted, now 11,945,856.
Claims priority of provisional application 63/420,999, filed on Oct. 31, 2022.
Claims priority of provisional application 63/416,852, filed on Oct. 17, 2022.
Claims priority of provisional application 63/397,773, filed on Aug. 12, 2022.
Claims priority of provisional application 63/304,478, filed on Jan. 28, 2022.
Prior Publication US 2024/0262886 A1, Aug. 8, 2024
Int. Cl. C07K 14/71 (2006.01); A61P 9/12 (2006.01)

CPC C07K 14/71 (2013.01) [A61P 9/12 (2018.01); C07K 2319/30 (2013.01)]

28 Claims

1. A nucleic acid molecule encoding a polypeptide comprising:

(a) an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant comprising the amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 2, wherein the ActRIIB-ECD variant comprises a substitution F58Q relative to the human wild type ActRIIB-ECD of SEQ ID NO: 2;

(b) a peptide linker comprising at least 10 amino acids; and